Myriad Genetics
Market Cap
US$1.8b
Last Updated
2019/12/05 23:40 UTC
Data Sources
Company Financials +
Executive Summary
Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests worldwide.
Rewards
Risk Analysis
Snowflake Analysis
Mediocre balance sheet with moderate growth potential.
Similar Companies
Share Price & News
How has Myriad Genetics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MYGN's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-1.5%
MYGN
-1.3%
US Biotechs
-1.2%
US Market
1 Year Return
-20.1%
MYGN
11.0%
US Biotechs
15.5%
US Market
Return vs Industry: MYGN underperformed the US Biotechs industry which returned 11% over the past year.
Return vs Market: MYGN underperformed the US Market which returned 15.5% over the past year.
Shareholder returns
| MYGN | Industry | Market | |
|---|---|---|---|
| 7 Day | -1.5% | -1.3% | -1.2% |
| 30 Day | 22.6% | 8.3% | 1.4% |
| 90 Day | 5.9% | 13.6% | 4.7% |
| 1 Year | -20.1%-20.1% | 12.0%11.0% | 18.0%15.5% |
| 3 Year | 51.1%51.1% | 27.4%23.4% | 44.8%35.4% |
| 5 Year | -26.9%-26.9% | 4.9%0.02% | 67.3%48.9% |
Price Volatility Vs. Market
How volatile is Myriad Genetics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Here's Why Myriad Genetics (NASDAQ:MYGN) Can Manage Its Debt Responsibly4 weeks ago | Simply Wall St
Earnings Update: Myriad Genetics, Inc. Just Reported And Analysts Are Trimming Their Forecasts1 month ago | Simply Wall St
Does Myriad Genetics, Inc.'s (NASDAQ:MYGN) CEO Pay Matter?Valuation
Is Myriad Genetics undervalued compared to its fair value and its price relative to the market?
1.78x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: MYGN ($25.67) is trading above our estimate of fair value ($19.11)
Significantly Below Fair Value: MYGN is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: MYGN is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: MYGN is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MYGN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MYGN is good value based on its PB Ratio (1.8x) compared to the US Biotechs industry average (3x).
Next Steps
Future Growth
How is Myriad Genetics forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
109.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MYGN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).
Earnings vs Market: MYGN is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: MYGN's is expected to become profitable in the next 3 years.
Revenue vs Market: MYGN's revenue (4.1% per year) is forecast to grow slower than the US market (7.4% per year).
High Growth Revenue: MYGN's revenue (4.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MYGN's Return on Equity is forecast to be low in 3 years time (7.8%).
Next Steps
Past Performance
How has Myriad Genetics performed over the past 5 years?
-22.8%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MYGN is currently unprofitable.
Growing Profit Margin: MYGN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MYGN is unprofitable, and losses have increased over the past 5 years at a rate of -22.8% per year.
Accelerating Growth: Unable to compare MYGN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MYGN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (103.3%).
Return on Equity
High ROE: MYGN has a negative Return on Equity (-1.43%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Myriad Genetics's financial position?
Financial Position Analysis
Short Term Liabilities: MYGN's short term assets ($329.5M) exceed its short term liabilities ($115.4M).
Long Term Liabilities: MYGN's short term assets ($329.5M) do not cover its long term liabilities ($401.3M).
Debt to Equity History and Analysis
Debt Level: MYGN's debt to equity ratio (20.9%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if MYGN's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: MYGN's debt is well covered by operating cash flow (40.8%).
Interest Coverage: MYGN is unprofitable, therefore interest payments are not well covered by earnings.
Balance Sheet
Inventory Level: MYGN has a low level of unsold assets or inventory.
Debt Coverage by Assets: MYGN's debt is covered by short term assets (assets are 1.5x debt).
Next Steps
Dividend
What is Myriad Genetics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate MYGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate MYGN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MYGN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MYGN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MYGN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
What is the CEO of Myriad Genetics's salary, the management and board of directors tenure and is there insider trading?
4.4yrs
Average management tenure
CEO
Mark Capone (57yo)
4.4yrs
Tenure
US$8,896,684
Compensation
Mr. Mark Christopher Capone has been the Chief Executive Officer and President at Myriad Genetics Inc. since July 1, 2015. Mr. Capone served as the President of Myriad Genetic Laboratories at Myriad Geneti ...
CEO Compensation Analysis
Compensation vs Market: Mark's total compensation ($USD8.90M) is above average for companies of similar size in the US market ($USD3.87M).
Compensation vs Earnings: Mark's compensation has increased whilst the company is unprofitable.
Management Age and Tenure
4.4yrs
Average Tenure
52yo
Average Age
Experienced Management: MYGN's management team is considered experienced (4.4 years average tenure).
Board Age and Tenure
9.9yrs
Average Tenure
66yo
Average Age
Experienced Board: MYGN's board of directors are considered experienced (9.9 years average tenure).
Insider Trading
Insider Buying: MYGN insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Chairman of the Board Independent Chairman |
| Shares | 7,000 |
| Max Price | US$23.46 |
| Entity | Individual |
| Shares | 1,975 |
| Max Price | US$31.00 |
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.5%.
Management Team
Gary King (63yo)
Executive Vice President of International Operations
- Tenure: 9.4yrs
Jerry Lanchbury (60yo)
Chief Scientific Officer
- Tenure: 9.8yrs
- Compensation: US$2.69m
Rishi Kacker
Chief Technology Officer
- Tenure: 1.4yrs
Scott Gleason
Vice President of Investor Relations
- Tenure: 0yrs
Mark Capone (57yo)
CEO, President & Director
- Tenure: 4.4yrs
- Compensation: US$8.90m
Ron Rogers (51yo)
Executive Vice President of Corporate Communications
- Tenure: 0yrs
R. Riggsbee (48yo)
Executive VP
- Tenure: 5.2yrs
- Compensation: US$3.14m
Alec Ford (52yo)
President of Myriad Women’s Health
- Tenure: 4.4yrs
- Compensation: US$3.23m
Ben Jackson (40yo)
Executive VP
- Tenure: 0.4yrs
Clivetty Martinez
Chief Compliance Officer
- Tenure: 0.9yrs
Board Members
Larry Best (70yo)
Independent Director
- Tenure: 10.3yrs
- Compensation: US$380.49k
Wally Gilbert (87yo)
Independent Vice Chairman
- Tenure: 0yrs
- Compensation: US$369.99k
John Henderson (75yo)
Independent Chairman
- Tenure: 14.7yrs
- Compensation: US$482.49k
Dennis Langer (67yo)
Independent Director
- Tenure: 15.6yrs
- Compensation: US$392.49k
Lee Newcomer (66yo)
Independent Director
- Tenure: 0.3yrs
Colleen Reitan (59yo)
Independent Director
- Tenure: 0.3yrs
Heiner Dreismann (66yo)
Independent Director
- Tenure: 9.5yrs
- Compensation: US$384.99k
Mark Capone (57yo)
CEO, President & Director
- Tenure: 4.4yrs
- Compensation: US$8.90m
S. Phanstiel (61yo)
Independent Director
- Tenure: 10.3yrs
- Compensation: US$399.49k
Company Information
Myriad Genetics, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Myriad Genetics, Inc.
- Ticker: MYGN
- Exchange: NasdaqGS
- Founded: 1991
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.843b
- Shares outstanding: 74.39m
- Website: https://myriad.com
Number of Employees
Location
- Myriad Genetics, Inc.
- 320 Wakara Way
- Salt Lake City
- Utah
- 84108
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| MYGN | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Oct 1995 |
| MYD | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Oct 1995 |
| 0K3W | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | Oct 1995 |
Biography
Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests worldwide. The company offers myRisk Hereditary Cancer, a DNA sequencing  ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/12/05 23:40 |
| End of Day Share Price | 2019/12/05 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2019/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.